RT @2Yackyack: @ClinpharmZono @3stars67664378 あら・・・くっついちゃいましたかね。 https://t.co/UL0ev5A5IK これと https://t.co/wkNwBTZRNg これと https://t.co/HYBh…
@ClinpharmZono @3stars67664378 あら・・・くっついちゃいましたかね。 https://t.co/UL0ev5A5IK これと https://t.co/wkNwBTZRNg これと https://t.co/HYBhoZIMQj これですね。全部フリーのはずです。
@by_the_HEY @3stars67664378 100mgと150mgではあんまり変わらなさそうかなぁと思いつつ、 https://t.co/a5Fi3WbyO9 このへんの報告を見ると https://t.co/oUBcrTC0Tt https://t.co/HYBhoZIMQj https://t.co/wkNwBTZRNg (特にMICが判明するまでは)2mg/kgあるいは150~200mgをスタンダードにして、減らす戦略もありなのかなぁ。
RT @AnnaNdamba: A 100 mg of micafungin might not be enough for critically ill obese patients. #OTILT @BWDionne @mmaleissa @G_loves_Pacman @…
RT @matdesgro: Antimicrobial dose optimization increasingly important because underdosing can kill ! Particularly at risk #obese critical…
RT @matdesgro: Antimicrobial dose optimization increasingly important because underdosing can kill ! Particularly at risk #obese critical…
RT @matdesgro: Antimicrobial dose optimization increasingly important because underdosing can kill ! Particularly at risk #obese critical…
RT @matdesgro: Antimicrobial dose optimization increasingly important because underdosing can kill ! Particularly at risk #obese critical…
Antimicrobial dose optimization increasingly important because underdosing can kill ! Particularly at risk #obese critically ill patient #antibiotics @IDstewardship @DEZ_EM_Pharm
RT @AnnaNdamba: A 100 mg of micafungin might not be enough for critically ill obese patients. #OTILT @BWDionne @mmaleissa @G_loves_Pacman @…
RT @AnnaNdamba: A 100 mg of micafungin might not be enough for critically ill obese patients. #OTILT @BWDionne @mmaleissa @G_loves_Pacman @…
RT @AnnaNdamba: A 100 mg of micafungin might not be enough for critically ill obese patients. #OTILT @BWDionne @mmaleissa @G_loves_Pacman @…
RT @AnnaNdamba: A 100 mg of micafungin might not be enough for critically ill obese patients. #OTILT @BWDionne @mmaleissa @G_loves_Pacman @…
A 100 mg of micafungin might not be enough for critically ill obese patients. #OTILT @BWDionne @mmaleissa @G_loves_Pacman @JennaKabBWH https://t.co/uRwsMG253j
@theABofPharmaC @BWDionne @TheIDApprentice @monipatt We recently had this exact debate at our institution. Here's another recent article for ya: https://t.co/7g0zUhNQ6l
RT @Crit_Care: Optimizing micafungin dosing in critically ill patients: what about extracorporeal therapies? #FOAMcc https://t.co/CcSX04d7R…
RT @FarMIC_SEFH: Hay que aumentar la dosis de micafungina a 150mg/24h en pacientes críticos obesos con infecciones por Candida albicans?? P…
Hay que aumentar la dosis de micafungina a 150mg/24h en pacientes críticos obesos con infecciones por Candida albicans?? Parece que si... https://t.co/jmMwfpWIck #
RT @Crit_Care: Optimizing micafungin dosing in critically ill patients: what about extracorporeal therapies? #FOAMcc https://t.co/CcSX04d7R…
RT @Crit_Care: Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly ob…
RT @Crit_Care: Optimizing micafungin dosing in critically ill patients: what about extracorporeal therapies? #FOAMcc https://t.co/CcSX04d7R…
RT @Crit_Care: Optimizing micafungin dosing in critically ill patients: what about extracorporeal therapies? #FOAMcc https://t.co/CcSX04d7R…
RT @Crit_Care: Optimizing micafungin dosing in critically ill patients: what about extracorporeal therapies? #FOAMcc https://t.co/CcSX04d7R…
RT @Crit_Care: Optimizing micafungin dosing in critically ill patients: what about extracorporeal therapies? #FOAMcc https://t.co/CcSX04d7R…
RT @MedCriticaMex: PK/PD of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients #FOAMcc…
PK/PD of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients #FOAMcc https://t.co/1Lz4P75LE5
RT @Crit_Care: Optimizing micafungin dosing in critically ill patients: what about extracorporeal therapies? #FOAMcc https://t.co/CcSX04d7R…
Optimizing micafungin dosing in critically ill patients: what about extracorporeal therapies? #FOAMcc https://t.co/CcSX04d7Ry
RT @Crit_Care: Are we near to the end of the standard dose of micafungin? #FOAMcc https://t.co/BeQhJWfJ1Z https://t.co/7mRf3SwC8L
RT @Crit_Care: Are we near to the end of the standard dose of micafungin? #FOAMcc https://t.co/BeQhJWfJ1Z https://t.co/7mRf3SwC8L
RT @Crit_Care: Are we near to the end of the standard dose of micafungin? #FOAMcc https://t.co/BeQhJWfJ1Z https://t.co/7mRf3SwC8L
Got this questions yesterday on micafungin dosing, new evidence suggests increasing micafungin to 150mg/day in the morbidly obese @sidp https://t.co/yNUQYSnMV7
RT @Crit_Care: Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly ob…
RT @Crit_Care: Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly ob…
RT @Crit_Care: Are we near to the end of the standard dose of micafungin? #FOAMcc https://t.co/BeQhJWfJ1Z https://t.co/7mRf3SwC8L
Are we near to the end of the standard dose of micafungin? #FOAMcc https://t.co/BeQhJWfJ1Z https://t.co/7mRf3SwC8L
RT @Crit_Care: Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly ob…
RT @Crit_Care: Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly ob…
RT @Crit_Care: Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly ob…
RT @Crit_Care: Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly ob…
RT @Crit_Care: Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly ob…
RT @Crit_Care: Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly ob…
RT @Crit_Care: Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly ob…
RT @SuarDelarica: Reconsideremos las dosis de antifúngicos en el paciente obeso https://t.co/olZCCy0dkD
Reconsideremos las dosis de antifúngicos en el paciente obeso https://t.co/olZCCy0dkD
RT @Crit_Care: Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly ob…
Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients. https://t.co/FcTxcdv8VV
RT @Crit_Care: Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly ob…
RT @Crit_Care: Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly ob…
RT @Crit_Care: Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly ob…
RT @Crit_Care: Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly ob…
Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients #FOAMcc https://t.co/5HUI6wL0rl
RT @EmilioMaseda: Take care with the dose of antifungal in critically ill population https://t.co/iiEhzN0pmF
RT @EmilioMaseda: Take care with the dose of antifungal in critically ill population https://t.co/iiEhzN0pmF
RT @EmilioMaseda: Take care with the dose of antifungal in critically ill population https://t.co/iiEhzN0pmF
RT @EmilioMaseda: Take care with the dose of antifungal in critically ill population https://t.co/iiEhzN0pmF
RT @EmilioMaseda: Take care with the dose of antifungal in critically ill population https://t.co/iiEhzN0pmF
Take care with the dose of antifungal in critically ill population https://t.co/iiEhzN0pmF